Forge A Successful CRISPR Therapeutic Path With High-Quality GMP sgRNA

The rapid increase in CRISPR-mediated cell and gene therapies in clinical trials over the past few years is a testimony to the promising future of next-generation medicine.

While improved technological prowess empowers the development of more CRISPR-edited therapies, supply-chain and manufacturing hurdles still pose significant barriers to clinical and commercialization timelines.

In this webinar, Synthego's Robert Deans, Chief Scientific Officer and Beckinam Nowatzke, Senior Director of Quality & Regulatory will elaborate on our preclinical and GMP offerings that support CRISPR therapy developers and accelerate time to clinic.